Skip to main content

Actinium Pharmaceuticals, Inc. (ATNM)

NYSEAMERICAN: ATNM · IEX Real-Time Price · USD
9.67 0.74 (8.29%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap206.27M
Revenue (ttm)888,000
Net Income (ttm)-22.26M
Shares Out20.23M
EPS (ttm)-1.27
PE Ration/a
Forward PE6.84
Dividendn/a
Ex-Dividend Daten/a
Volume1,113,667
Open8.98
Previous Close8.93
Day's Range8.71 - 10.30
52-Week Range5.70 - 13.18
Beta1.03
AnalystsBuy
Price Target32.50 (+236.1%)
Est. Earnings DateOct 22, 2021

About ATNM

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a mu...

IndustryBiotechnology
Founded2000
CEOSandesh Seth
Employees32
Stock ExchangeNYSEAMERICAN
Ticker SymbolATNM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ATNM stock is "Buy." The 12-month stock price forecast is 32.50, which is an increase of 236.09% from the latest price.

Price Target
$32.50
(236.09% upside)
Analyst Consensus: Buy

News

Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and Commercial Officer, New Chief...

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unm...

3 days ago - PRNewsWire

Actinium to Present at Four Upcoming Investor Conferences

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unm...

6 days ago - PRNewsWire

BWXT Medical, Bayer AG Ink Agreement On Actinium-225

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com Trending

1 week ago - Benzinga

Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it has completed enrollment of the pivotal Phase 3 SIERR...

1 week ago - PRNewsWire

Actinium Pharmaceuticals Announces Inclusion in Russell Microcap® Index

NEW YORK, June 28, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced today that it will be added to the Russell Microcap® Index at t...

2 months ago - PRNewsWire

Actinium Further Strengthens Patent Portfolio with International IP Covering the Composition and Methods of Administr...

NEW YORK, June 17, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its intellectual property portfolio around its lead Phase...

3 months ago - PRNewsWire

Actinium's Targeted Radiotherapy Achieves 100% Bone Marrow Transplant Engraftment

Actinium Pharmaceuticals Inc (NYSE: ATNM) highlighted data from its pivotal Phase 3 SIERRA trial evaluating Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (AML) aged 55 years and...

3 months ago - Benzinga

Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment in Patients Treated with Iomab-B pr...

NEW YORK, June 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted data from its pivotal Phase 3 SIERRA trial for Iomab-B in an...

3 months ago - PRNewsWire

Safety Data Highlighting Low Rates of Adverse Events and Non-Relapse Transplant Related Mortality in Patients Receivi...

NEW YORK, June 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") today highlighted safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patie...

3 months ago - PRNewsWire

Surging Earnings Estimates Signal Good News for Actinium (ATNM)

Actinium (ATNM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

3 months ago - Zacks Investment Research

Actinium Activates Radiation Inside the Body for Target Conditioning of Cancer Cells

Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company, is developing antibody radiation-conjugates (ARCs) to combine the targeting ability of antibodies with the cell-ki...

3 months ago - Benzinga

Actinium Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Me...

NEW YORK, June 3, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that three abstracts highlighting data and findings from the Co...

3 months ago - PRNewsWire

7 Reddit Penny Stocks Promising to Cure Cancer

These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on I...

4 months ago - InvestorPlace

Actinium to Participate in the Cell & Gene Meeting on the Mediterranean

NEW YORK, March 31, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Cell & Gene Meeting on t...

5 months ago - PRNewsWire

Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patie...

NEW YORK, March 25, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that initial patient enrollment in the second dose cohort in ...

6 months ago - PRNewsWire

Anthem, Inc. To Acquire myNEXUS, Home Health Benefits Manager

INDIANAPOLIS--(BUSINESS WIRE)--Anthem, Inc. (NYSE: ATNM) today announced that the company has entered into an agreement to acquire myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing managemen...

6 months ago - Business Wire

Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-...

NEW YORK, March 24, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its collaborator, Memorial Sloan Kettering Cancer Center...

6 months ago - PRNewsWire

Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD...

NEW YORK, March 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that preclinical feasibility data supporting an Actinium-225-...

6 months ago - PRNewsWire

Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference

NEW YORK, March 2, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that management will participate in the H.C. Wainwright (HCW) Global Life Scienc...

6 months ago - PRNewsWire

Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 S...

NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its presence at the 2021 Transplantation & Cellular Therapy (...

7 months ago - PRNewsWire

Actinium Announces Participation in BIO CEO & Investor Digital Conference

NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that management will participate in the BIO CEO & Investor conf...

7 months ago - PRNewsWire

Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference

NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that members of its executive team will participate in a fireside chat at the B....

8 months ago - PRNewsWire

Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas") to ...

8 months ago - PRNewsWire

Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial

NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that the independent Data Monitoring Committee (DMC) has comple...

8 months ago - PRNewsWire

Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know

Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $11.22, moving +0.9% from the previous trading session.

9 months ago - Zacks Investment Research